Page 2454 - Williams Hematology ( PDFDrive )

2425
2424 Index Index 2425

DTIC (dimethyltriazenoimidazole E2F transcription factor, 217 EGPA (eosinophilic granulomatosis with
carboxamide), 329 EACA. See ε-aminocaproic acid (EACA) polyangiitis), 959–960, 2107
DTS (dense tubular system), 1836 Early T-cell precursor acute lymphoblastic EGR1, 234t, 1737
Dubowitz syndrome, 530t leukemia, 1512, 1512t EGR2, 231t
Duffy antigen receptor for chemokines Ears, history of disorders of, 5 Ehlers-Danlos syndrome, 1986, 1987, 2061,
(DARC), 285 Eastern Cooperative Oncology Group 2108
Duffy blood group, 104, 2331t, 2335t, 2337, Performance Status, 3, 4t Eicosanoid metabolism, 1856, 1857f
2345t EATL (enteropathy-associated T-cell Eicosanoid pathway, 1969–1970
Duncan syndrome, 1266 lymphoma), 1694t, 1699–1700 Eicosanoids, 1967, 1968t
Duodenal cytochrome b, 621t EBF, 1155 Eicosapentaenoic acid, 2079
DUSP22 (DUSP22), 1696, 1699 EBF1, 236t, 1644 Eisenmenger syndrome, erythrocytosis of,
dU (deoxyuridine) suppression test, 594, 598, EBIs (erythroblastic islands), 64, 462–463, 872, 876, 881
603 462f EKLF (erythroid Kruppel-like factor), 484
Dutcher-Fahey bodies, 1791 E box-binding proteins, 195, 270 ELANE, 983, 993, 994
DVT. See Deep vein thrombosis (DVT) EBV infections. See Epstein-Barr virus (EBV) Elastase, 283, 1012t, 1013
Dyserythropoiesis, 473, 563. See also infections Electron beam therapy, 1686
Congenital dyserythropoietic EBVP regimen, for Hodgkin lymphoma, Electron transport chain (ETC), 196
anemias (CDAs) 1611 Eliglustat tartrate, 1128
Dysfibrinogenemia/hypodysfibrinogenemia, E-cadherin, 657 Elinogrel, 2076
2157–2159 Ecchymoses, 6, 8, 1987 Elliptocytes (ovalocytes), 473, 474f
acquired, 2159 Echinocandins, 385, 389 abnormal, 671f, 679. See also Hereditary
clinical features, 2158 Echinococcus, 957t elliptocytosis (HE)
definition, history, and epidemiology, Echinocytes, 21f, 472f, 472t, 474f, 671f, 680 characteristics, 472t
2157–2158, 2157f Eclampsia, 122, 801–802, 2011, 2210–2211 disease states associated with, 472t
differential diagnosis, 2159 ECMs (extracellular matrix proteins), 61–62 Elongin-C, 487
etiology and pathogenesis, 2158 ECP (eosinophil cationic protein), 929, 931, Elotuzumab
laboratory features, 2159 953 mechanism of action, 1755
in pregnancy, 2159 Ecto-ATP/Dase-1. See CD39 (ecto-ATP/ for myeloma, 345, 345f, 346t, 1754t, 1755
therapy, 2159 Dase-1/CD39) Eltrombopag
Dyshemoglobins/dyshemoglobinemias, 789 Ectoenzymes, 1143–1144, 1144t adverse effects, 2006
carboxyhemoglobin, 795–796 Eculizumab for aplastic anemia, 526
low-oxygen-affinity hemoglobins, 794– for atypical hemolytic uremic syndrome, for hypersplenism, 867
795, 794t 2261 for immune thrombocytopenia, 2006
methemoglobinemia. See contraindication during pregnancy, 580 for myelodysplastic syndromes, 1358
Methemoglobinemia for hemolytic anemia, 839 for platelet count elevation before surgery,
nitric oxide hemoglobins, 796–797, 796f, mechanism of action, 572f, 836 2194
797f meningococcal infections and, 578, 581 EM (erythema multiforme), 2106, 2106f
sulfhemoglobin, 793–794 for paroxysmal nocturnal hemoglobinuria, Embden-Meyerhof (glycolytic) pathway,
Dyskeratosis congenita, 530–532, 531f, 531t 576t, 578, 580, 581 692–694, 693f, 932, 933t
Dyskerin, 530–531, 531f Edema, history of, 6 Emberger syndrome, 1098, 1351, 1379
Dysmorphia of neoplasia, 1342 EDN (eosinophil-derived neurotoxin), 931, Embolism/emboli
Dysphagia, 5, 632 953 amniotic fluid, 2210
Dysplasia, 1343 Edoxaban, 402 atheromatous, 2298
Dyspnea, 5 clinical studies, 401t cholesterol, 2101, 2102f
Dysproteinemias mechanism of action, 1922 from intracardiac thrombi, 2102
cryofibrinogenemia, 2099 for venous thromboembolism, 2274–2275, pulmonary. See Pulmonary embolism
cryoglobulinemia, 2097, 2099f 2274t, 2275t Embryogenesis, stem cell development and,
light-chain vasculopathy, 2099 EDRF (endothelium-derived relaxing factor). 54
platelet dysfunction in, 2082 See Nitric oxide (NO) Embryonic erythropoiesis, 480
Waldenström hyperglobulinemic purpura, EDTA (ethylenediaminetetraacetic acid), Embryonic stem cells (ESCs), 448–449, 450
2099, 2099f 1994, 1995, 2339 EMMPRIN, 1869
EEC (endogenous erythroid colonies), 1292 Emp, 481
E EGF (epidermal growth factor), 1848 EMR1 (F4/80), 1079–1080, 1081f, 1082
E2A, 270, 1155 EGF-TM7 (epidermal growth factor-seven EMR2, 1059, 1080, 1081f
E2A-HLF, 1510 transmembrane), 1059 EMZL. See Extranodal marginal zone
E2A-PBX1 (TCF3-PBX1), 1507, 1516 EGLN1, 875, 878 lymphoma of MALT type

Kaushansky_index_p2393-2506.indd 2425 9/21/15 3:21 PM